In symptomatic PAH, adding sotatercept to stable background therapy improved 6-min walk distance at 24 wk

Rodolfo A. Estrada

doi:10.7326/J23-0034

In symptomatic PAH, adding sotatercept to stable background therapy improved 6-min walk distance at 24 wk

Rodolfo A. Estrada

Division of Pulmonary Diseases

Producción científica: Comment/debate › revisión exhaustiva

Resumen

SOURCE CITATION: Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388:1478-1490. 36877098.

Idioma original	English (US)
Páginas (desde-hasta)	JC69
Publicación	Annals of internal medicine
Volumen	176
N.º	6
DOI	https://doi.org/10.7326/J23-0034
Estado	Published - jun 1 2023

ASJC Scopus subject areas

Internal Medicine

Acceder al documento

10.7326/J23-0034

Otros archivos y enlaces

Citar esto

@article{38572991766044aab1909708d7369cfb,

title = "In symptomatic PAH, adding sotatercept to stable background therapy improved 6-min walk distance at 24 wk",

abstract = "SOURCE CITATION: Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388:1478-1490. 36877098.",

author = "Estrada, \{Rodolfo A.\}",

year = "2023",

month = jun,

day = "1",

doi = "10.7326/J23-0034",

language = "English (US)",

volume = "176",

pages = "JC69",

journal = "Annals of internal medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "6",

}

TY - JOUR

T1 - In symptomatic PAH, adding sotatercept to stable background therapy improved 6-min walk distance at 24 wk

AU - Estrada, Rodolfo A.

PY - 2023/6/1

Y1 - 2023/6/1

N2 - SOURCE CITATION: Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388:1478-1490. 36877098.

AB - SOURCE CITATION: Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388:1478-1490. 36877098.

UR - https://www.scopus.com/pages/publications/85163920640

UR - https://www.scopus.com/pages/publications/85163920640#tab=citedBy

U2 - 10.7326/J23-0034

DO - 10.7326/J23-0034

M3 - Comment/debate

C2 - 37276594

AN - SCOPUS:85163920640

SN - 0003-4819

VL - 176

SP - JC69

JO - Annals of internal medicine

JF - Annals of internal medicine

IS - 6

ER -

In symptomatic PAH, adding sotatercept to stable background therapy improved 6-min walk distance at 24 wk

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto